Full history for every metric is available with a Kvantra account
Chinook Therapeutics, Inc. (KDNY)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 17 | 15 | 17 | 1 | 52 | 6 | 6 |
| Operating profit | $m | -185 | -252 | |||||
| Net profit | $m | -92 | -95 | -47 | -82 | -101 | -185 | -243 |
| EPS reported | $ | -2.87 | -3.48 | |||||
| Operating cashflow per share | $ | -1.83 | -1.83 | |||||
| Capex per share | $ | 0.03 | 0.03 | |||||
| FCF per share | $ | -1.85 | -1.85 | |||||
| Free cash flow | $m | -119 | -177 | |||||
| Net debt | $m | -339 | -297 | |||||
| Book value equity | $m | 442 | 357 | |||||
| Book value per share | $ | 6.87 | 4.99 | |||||
| Number of shares | m | 64.37 | 71.59 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.82 | 7.58 | |||||
| P/S LTM | x | 275.21 | 463.01 | |||||
| P/FCF LTM | x | -14.16 | -15.33 | |||||
| EV/EBITDA LTM | x | -9.81 | -10.94 | |||||
| EV/Sales LTM | x | 262.81 | 412.20 | |||||
| Earnings Yield LTM | % | -10.95% | -7.10% | |||||
| FCF Yield | % | -7.06% | -6.52% | |||||
| Quality | ||||||||
| ROE | % | -41.77% | -41.23% | |||||
| ROIC | % | -35.04% | -35.04% | |||||
| Operating margin | % | -3020.3% | -3020.3% | |||||
| Gross margin | % | 71.90% | 71.90% | |||||
| FCF/Sales | % | -1944.1% | -1944.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -88.13% | -89.24% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.02 | -5.20 | |||||
| Net Debt/EBITDA | x | 0.46 | 0.46 | |||||
| EBIT/Net interest | x | -25.78 | -25.78 | |||||
| Net debt/market cap | % | -20.09% | -10.97% | |||||
| Net debt/Equity | x | -0.77 | -0.83 | |||||
| Gross debt/equity | x | 0.09 | 0.10 | |||||
Company overview
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Chinook Therapeutics, Inc. (KDNY)
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free